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Methamphetamine (MA) is a drug that is widely used in many parts of the world. It has
multiple neurobiological impacts on the nervous system; some of which are transitory and
some longer lasting. MA activates the reward system of the brain and produces effects that
are highly reinforcing, which can lead to abuse and dependence. Routes of administration
that produce rapid onset of the drug effects (i.e., smoking and injection) are likely to lead to
more rapid addiction and more medical and psychiatric effects. The medical effects of MA
use are extensive, and chronic use of MA can produce significant neurological damage as
well as damage to cardiovascular, pulmonary, and other organ systems. Both acute and
chronic MA use can lead to extreme paranoia, anxiety, and depression, and following
discontinuation of MA use, cognitive deficits, and anhedonia can persist for several
months. No effective pharmacotherapies have been developed for MA dependence,
although this is an area of active research. Several behavioral treatments have been shown
to reduce MA use, but better treatments are needed. The research agenda for MA is sub-
stantial, with development of effective pharmacotherapies as one of the most important
priorities.
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LLC.Open access under CC BY-NC-ND license.1. Introduction the world reside in East and Southeast Asia, followed byWorldwide, as many as 52 million individuals aged 15e64
years are estimated to have used amphetamine-type stim-
ulants for nonmedical purposes at least once in the past
year. Methamphetamine (MA) is the second most widely
abused illicit drug in the world (following cannabis); its
users nearly outnumber heroin and cocaine users com-
bined. About two-thirds of the MA/amphetamine users inms, 11075 Santa Monica
u.
ministration, Taiwan. Publapproximately one-fifth in the Americas (specifically the
United States and Northern Mexico). MA is a substantial
problem in many Asian countries, including Brunei,
Cambodia, Japan, and Thailand, which report MA as their
number one drug problem, and indicators of abuse, pro-
duction, and trafficking of MA show signs of increased use
in several other Asian countries, including China and
Vietnam.Boulevard, Suite 100, Los Angeles, CA 90025-7535, USA.
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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MA increases activation of the dopamine, norepinephrine,
and serotonin systems. MA use causes release of dopamine
into the synaptic cleft, increasing dopamine concentration.
Furthermore, MA inhibits transport of dopamine into the
storage vesicles, thus increasing the synaptic dopamine con-
centration. This abnormally high concentration of dopamine
contributes to the severe neurotoxicity of MA. Heavy daily MA
use and high dosages over a long duration result in neurobi-
ological deficits that do not resolve until many months
following cessation of use [1e3].
Besides the acute dopaminergic stimulation, MA produces
norepinephrine effects such as mild elevation of pulse and
blood pressure and cutaneous vasoconstriction. Higher doses
increase central nervous system stimulation, manifested as
increased alertness and compulsive or repetitive behavior.
MA users have increased sympathomimetic effects such as
dizziness, tremor, hyperreflexia (rapid reflexes), pyrexia
(fever), mydriasis (dilated pupils), diaphoresis (sweating),
tachypnea (rapid breathing), tachycardia (rapid heartbeat),
and hypertension (high blood pressure) [4]. The drug has a
prolonged half-life (10e12 hours) and long duration of action.
The reinforcing effects of MA are mediated through the mes-
olimbic dopamine reward system, which includes dopami-
nergic projections from the ventral tegmental area of the brain
to the nucleus accumbens and other forebrain structures.
Elevated levels of dopamine in the central nervous system are
associated with the reinforcing and highly addictive proper-
ties of MA.3. Route of administration
MA can be used orally or intranasally, or it can be smoked or
injected intravenously. Injection and smoking of MA carry a
higher risk for acute toxicity aswell as greater potential for the
development of addiction. In general, the rapid onset of
euphoria provided by these routes of administration provides
a powerful stimulus for readministration of the drug to
maintain the euphoria. When injected intravenously, MA
reaches the cerebral circulation in 10e15 seconds. When
smoked, it reaches the brain in 6e8 seconds; smoking can
achieve blood levels comparable to those reached through
intravenous injection [5,6]. These routes also have the most
potential for toxicity due to rapid dose escalation. Intranasal
insufflation (“snorting”) of MA produces euphoria in 3e5 mi-
nutes [6]. Absorption of orally administered MA occurs more
slowly from the intestines, with peak plasma levels being
reached 180 minutes after dosing [7]. Clinical reports recount
dependence-level users taking 50e1000 mg of MA daily.4. Symptoms of MA use, misuse, and
dependence
MA use increases blood pressure, body temperature, heart
rate, and breathing rate. Continued use is common because of
rewarding effects such as euphoria, reduced fatigue, reducedhunger, increased energy, increased sex drive, and increased
self-confidence. Negative acute effects include abdominal
cramps, shaking, high body temperature, bruxism (teeth
grinding), stroke, and cardiac arrhythmia, as well as increased
anxiety, insomnia, aggressive tendencies, paranoia, and
hallucinations.
The acute subjective effects of MA use depend on the
amount used and route of administration. The effects of in-
jection and smoking are rapid and intense, often described as
a “rush”, followed by euphoria and a sense of increased en-
ergy, wakefulness, alertness, and increased libido. Heart rate,
blood pressure, and breathing rate increase, and many users
will grind their teeth and pick at their skin. Effects of MA can
last up to 12 hours. Due to the development of tolerance,
chronic MA users repeat dosing every few hours in “binging”
episodes, which can result in paranoia, hallucinations, de-
lusions, mood disturbance, and formication (tactile halluci-
nation of bugs crawling on the skin).
After prolonged or heavy use of MA, a withdrawal syn-
drome may emerge characterized by dysphoric mood,
anhedonia, fatigue, increased appetite, sleep disturbance,
and slowing or acceleration of psychomotor activity [8]. The
severity of withdrawal is related to the duration and in-
tensity of recent MA use [9]. MA-dependent individuals have
reported remission of the most severe withdrawal symp-
toms within several days to 3 weeks, although there have
been numerous clinical observations of more subtle symp-
toms (i.e., anhedonia) lasting for several months [10,11].
Apathy has been reported more frequently than depressed
mood, suggesting that anhedonia may be more problematic
than major depressive disorder following cessation of MA
use [12].5. Psychiatric considerations
MA-associated psychiatric impairment may occur in several
domains: cognitive, intellectual, or affective. The contribution
of the drug to impairment may be acute, delayed, or cumu-
lative/residual. Psychiatric impairment appears to correlate
with duration of use as well as total and peak amounts of MA
absorbed. Neurocognitive deficits associated with chronic MA
use include impairments in episodic memory, executive
functions, and psychomotor tasks related to frontostriatal and
limbic circuits. MA use may also be associated with deficits
in attention, memory, and language [13]. Neurocognitive
impairment may persist for 9 months or longer following
cessation of MA use, but recovery in dopamine transporter
activity and improvement in cognitive functioning is possible
with sustained abstinence [14,15].
Psychiatric symptoms have been well documented in MA
users [16]. Anxiety, depression, insomnia, and psychosis are
among the most commonly reported symptoms associated
with MA dependence, and individuals presenting to the
emergency department in the context of MA intoxication may
be agitated, violent, or suicidal [17,18]. Although minor agita-
tion may be treated by placing the individual in a quiet, less-
stimulating environment, benzodiazepines or neuroleptics
may be required for more severe MA-related agitation or
psychosis [18].
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differences in sensitivity to MA, amount and/or frequency of
use, and route of administration [19]. Individuals who use MA
intravenously and who have a family history of psychotic
symptoms are at heightened risk for the development of MA-
related psychosis, which may mimic schizophrenia. Clinical
symptoms of MA-induced psychosis include paranoia, de-
lusions, and hallucinations [20,21]. Psychosis occurs at least
intermittently in a significant proportion of MA users, with a
wide variation in the severity and clinical course of symptoms
[20]. Although the majority of MA-related psychiatric symp-
toms typically remit within a week of abstinence [12], a subset
of MA users experience prolonged psychiatric symptom-
atology, even in the absence of a prior reported history of
mental illness [22,23].6. Medical considerations
Chronic use of MA results in a variety of medical conse-
quences, including: (1) cardiovascular disease e arrhythmia
and coronary artery damage are particularly prevalent,
occurring at a much younger age among MAmisusers than in
the general population [24]; (2) pulmonary problems e
including pneumonia are common, particularly among in-
dividuals who smoke MA; (3) liver disease e found in 40% of
MA misusers by autopsy [24]; (4) strokes emay occur in even
young MA misusers by all routes of administration, resulting
in long-term neuronal damage [25,26]; hemorrhage or
ischemia typically occurs in frontal lobes [24]; (5) pregnancy
complications e use of MA by pregnant women endangers the
fetus; for example, use of MA has been associated with a 3.5
times greater likelihood of reduced birth weight compared to
non-MA-using controls [27]; (6) neurological complications e
MA use can produce movement disorders [28], toniceclonic
seizures, and cerebrovascular accidents [29], hyperkinetic
movements including repetitive or stereotyped behaviors
[28,30], and choreoathetoid movement disorders [31,32]; and
(7) dental complications e an emerging body of literature
suggests an association between MA dependence and dental
pathology, including rampant caries (cavities), missing and
fractured teeth, and periodontal disease [33e35].
Long-term MA use is associated with elevated rates of in-
fectious diseases, including human immunodeficiency virus
(HIV), hepatitis B and C, and endocarditis [18]. Factors medi-
ating the relationship betweenMAuse and infectious diseases
include increased risky sexual behaviors occurring in the
context of MA intoxication, as well as injection drug use and
associated risk behaviors (e.g., needle sharing) [36].7. Clinical considerations
The groups disproportionately affected by MA are women as
well as men who have sex with men (MSM). Unlike with
cocaine and heroin, where a high proportion of users aremen,
women use MA at rates almost equal to men. Surveys among
women suggest that they are more likely than men to be
attracted to MA for weight loss and to control symptoms
of depression. Over 70% of MA-dependent women reporthistories of physical and sexual abuse and are more likely
than men to present for treatment with greater psychological
distress. MA has been a popular drug among MSM since the
1980s. MSM report using MA to combat feelings of loneliness
and isolation and to promote sexual desire and sexual
behavior [37,38]. In addition to the appeal of its sexual effects,
MA serves as a coping tool for many MSM with HIV or AIDS.
MSM with HIV report using MA to manage symptoms of HIV
disease, such as fatigue, or to remedy HIV-related “burn out”
and depression [37].
The dramatic effect of MA on sexual desire and sexual
behavior has been a major public health concern, because it
has been associated with an increasing risk for the trans-
mission of HIV [37,39]. Sexual practices associated with MA
use include increased numbers of casual and anonymous
sexual partners, increased anal intercourse, decreased
condom use, sex trading, group sex, and more frequent and
longer episodes of sexual activity [40e42]. The Multicentre
AIDS Cohort Study and several other studies found a high
correlation between MA use and HIV seroconversion [40] and
other sexually transmitted infections, such as syphilis,
gonorrhea, and hepatitis [43e45]. Treatment of MA depen-
dence may be one of the most effective strategies in reducing
the spread of HIV and other associated sexually transmitted
infections.8. Pharmacotherapy treatments
To date, there is limited literature on evidence-based phar-
macological treatment approaches for MA withdrawal. Anti-
depressants and anxiolytics may be used to ameliorate
depressive and anxiety symptoms, although research suggests
only limited benefits of antidepressants in reducing with-
drawal symptoms [46]. Neuroleptics may be used to treat MA-
induced psychotic symptoms in the context of intoxication or
recent use [47], and a recent study demonstrated the equiva-
lent efficacy of olanzapine, an atypical neuroleptic, and halo-
peridol, a typical neuroleptic, in improving psychotic
symptoms related to amphetamine use [48].
The research literature lacks substantiation of efficacy of
any medication as a treatment for MA dependence. Past work
has failed to determine efficacy of compounds such as sele-
gilene, sertraline, gabapentin, rivastigmine, risperidone, and
ondansetron [49] as potential treatments for MA dependence.
Medication development forMA addiction generally strives
to address deficits caused by MA use or associated with
withdrawal. The target of therapeutic development has
focused on initiation of abstinence and prevention of relapse.
Bupropion, modafinil, naltrexone, mirtazapine, and baclofen
have exhibited limited utility in treating MA addiction. Other
medications (e.g., lobeline and vigabatrin) are under consid-
eration, but evidence for efficacy is lacking and the scant data
that do exist contain no information regarding suitability for
various populations. Also of interest is a replacement or sub-
stitution approach with other stimulants such as methyl-
phenidate [50,51], akin to methadone for opioid addiction. As
with methadone, however, such pharmacotherapy enables
the patient to rehabilitate in other life areas but does not lead
to near-term abstinence from stimulants.
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therapy
The Matrix Model incorporates principles of cognitive behav-
ioral therapy (CBT) in individual and group settings, family
education, motivational interviewing, and behavioral therapy
that employs CBT principles. This manualized therapy has
been proven effective in reducing MA use during 16 weeks
application of the intervention, in comparison to a “treatment
as usual” condition [52,53]. The Matrix Model has been eval-
uated as a stand-alone treatment for subgroups of MA abusers
(e.g., gay and bisexual men and heterosexuals) and as the
behavioral treatment platform in pharmacotherapy trials for
MA dependence [54].10. Contingency management
Contingency management (CM) therapy for the treatment of
stimulant use disorders uses principles of reinforcement for
demonstration of desired behaviors. Drug use can be brought
under control if desired behaviors that replace or compete with
drug use are followed by rewards to increase the frequency of
these behaviors. Thus, CM combined with a pharmacotherapy,
such as modafinil, that potentially enhances cognition or re-
storesmemory/learningprocesses impactedbyMAdependence
could be a potent approach. CMandCBThave been assessed for
comparative effectiveness in treating stimulant dependence
with a group of cocaine- and MA-dependent individuals e par-
ticipants who received CM were retained in treatment signifi-
cantly longer than those who received only CBT and they
provided more stimulant-negative urine samples [53].11. Conclusions
MA is widely used in many parts of the world and produces
significant acute and chronic medical and psychiatric condi-
tions. Currently, there are no medications that have shown
evidence of efficacy in the treatment of MA dependence.
Several behavioral treatments have been shown to reduce MA
use, but additional treatments are needed to provide a suffi-
cient set of clinical tools to treat adequately the majority
of MA-dependent individuals. The development of effective
treatments that can reduce the use of MA as well as its
consequent medical and psychiatric comorbidities is an
important priority for future research.r e f e r e n c e s
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